EIK1001 — Full data
2H 2026
Full Phase 2 NSCLC data readout | 2H 2026Source filing
EIKN biotech catalysts & pipeline
EIKON THERAPEUTICS INC · Data as of 2026-10-27
Upcoming catalysts
EIK1003 — Full data
2H 2026
Full read out of Phase 1/2 study | 2H 2026Source filing
EIK1004 — Initial data
2H 2026
Initial data from Phase 1/2 study | 2H 2026Source filing
EIK1005 — Initial data
2H 2026
Initial data from Phase 1/2 study | 2H 2026Source filing
EIK1006 — IND submission
Late 2026
Eikon expects to submit an investigational new drug application (IND) for EIK1006 by the end of 2026.Source filing
EIK1001 — Interim data
1H2027
Second interim analysis to proceed to Ph3 for melanoma study | 1H2027Source filing
EIK1005 — Clinical data readout
H1 2027
Eikon expects additional results from the combination of EIK1005 with pembrolizumab to be available in the first half of 2027, with complete results for EIK1005 monotherapy available in the second half of 2027.Source filing
EIK1001 — Interim data
H2 2027
Eikon expects to conduct a first interim analysis to select the single dose of EIK1001 to take forward for the remainder of this trial in the second half of 2027.Source filing
EIK1003 — Clinical data readout
H2 2027
Eikon is currently enrolling an additional Cohort 1D evaluating EIK1003 in combination with paclitaxel and platinum-based chemotherapy, for which initial results are expected in the second half of 2027.Source filing
EIK1004 — Clinical data readout
H2 2027
Eikon plans to initiate a combination arm of EIK1004-001 evaluating EIK1004 in combination with docetaxel, with plans to report initial results from that combination arm in the second half of 2027.Source filing
EIK1005 — Full data
H2 2027
Eikon expects additional results from the combination of EIK1005 with pembrolizumab to be available in the first half of 2027, with complete results for EIK1005 monotherapy available in the second half of 2027.Source filing